ECM1 and TMPRSS4 Are Diagnostic Markers of Malignant Thyroid Neoplasms and Improve the Accuracy of Fine Needle Aspiration Biopsy
- 1 September 2005
- journal article
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 242 (3) , 353-363
- https://doi.org/10.1097/01.sla.0000179623.87329.6b
Abstract
The objective of this study was to determine whether genes that regulate cellular invasion and metastasis are differentially expressed and could serve as diagnostic markers of malignant thyroid nodules. Patients whose thyroid nodules have indeterminate or suspicious cytologic features on fine needle aspiration (FNA) biopsy require thyroidectomy because of a 20% to 30% risk of thyroid cancer. Cell invasion and metastasis is a hallmark of malignant phenotype; therefore, genes that regulate these processes might be differentially expressed and could serve as diagnostic markers of malignancy. Differentially expressed genes (2-fold higher or lower) in malignant versus benign thyroid neoplasms were identified by extracellular matrix and adhesion molecule cDNA array analysis and confirmed by real-time quantitative polymerase chain reaction (PCR). The area under the receiver operating characteristic (AUC) curve was calculated to determine diagnostic accuracy of gene expression level cutoffs established by logistic regression analysis. By cDNA array analysis, ADAMTS8, ECM1, MMP8, PLAU, SELP, and TMPRSS4 were upregulated, and by quantitative PCR, ECM1, SELP, and TMPRSS4 mRNA expression was higher in malignant (n = 57) than in benign (n = 38) thyroid neoplasms (P< 0.002). ECM1 and TMPRSS4 mRNA expression levels were independent predictors of a malignant thyroid neoplasm (P < 0.003). The AUC was 0.956 for ECM1 and 0.926 for TMPRSS4. Combining both markers improved their diagnostic use (AUC 0.985; sensitivity, 91.7%; specificity, 89.8%; positive predictive value, 85.7%; negative predictive value, 82.8%). ECM1 and TMPRSS4 expression analysis improved the diagnostic accuracy of FNA biopsy in 35 of 38 indeterminate or suspicious results. The level of ECM1 mRNA expression was higher in TNM stage I differentiated thyroid cancers than in stage II and III tumors (P ≤ 0.031). ECM1 and TMPRSS4 are excellent diagnostic markers of malignant thyroid nodules and may be used to improve the diagnostic accuracy of FNA biopsy. ECM1 is also a marker of the extent of disease in differentiated thyroid cancers.Keywords
This publication has 104 references indexed in Scilit:
- Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survivalCancer, 2004
- Genome-Wide Profiling of Papillary Thyroid Cancer Identifies MUC1 as an Independent Prognostic MarkerCancer Research, 2004
- Practice, Efficacy, and Costs of Thyroid Nodule Evaluation: A Retrospective Study in a Dutch University HospitalThyroid®, 2004
- The Use of a Combination of Galectin-3 and Thyroid Peroxidase for the Diagnosis and Prognosis of Thyroid CancerAmerican Journal of Clinical Pathology, 2004
- The Quest for a Magic Tumor MarkerAmerican Journal of Clinical Pathology, 2002
- Distinct frequency ofret rearrangements in papillary thyroid carcinomas of children and adults from BelarusInternational Journal of Cancer, 1999
- Reverse Transcriptase-Polymerase Chain Reaction Analysis of Thyrocyte-Relevant Genes in Fine-Needle Aspiration Biopsies of the Human ThyroidThyroid®, 1998
- Characterization of the human extracellular matrix protein 1 gene on chromosome 1q21Matrix Biology, 1997
- Expression of the RET/PTC Fusion Gene as a Marker for Papillary Carcinoma in Hashimoto's ThyroiditisThe Laryngoscope, 1997
- p53 gene mutation in thyroid carcinomaCancer Letters, 1996